医学
布仑妥昔单抗维多汀
耐火材料(行星科学)
不利影响
内科学
肿瘤科
临床研究阶段
随机对照试验
临床试验
淋巴瘤
外科
CD30
天体生物学
物理
作者
Stephanie Sasse,Paul J. Bröckelmann,Jesko Momotow,Annette Plütschow,Andreas Hüttmann,Nadežda Basara,Christian Koenecke,Sonja Martin,Martin Bentz,Christina Große-Thie,Sven Thorspecken,Maike de Wit,Carsten Kobe,Markus Dietlein,Bastian von Tresckow,Michael Fuchs,Peter Borchmann,Andreas Engert
标识
DOI:10.1080/10428194.2022.2095623
摘要
In patients with relapse of classical Hodgkin lymphoma (cHL) after autologous stem cell transplant, brentuximab vedotin and anti-PD1 treatment, the outcome is poor. To assess the efficacy of the bispecific anti-CD30/CD16A, NK-cell engaging antibody AFM13 and to select the optimal treatment schedule (arm A–C), we initiated a randomized two-stage phase II trial (NCT02321592). Due to slow recruitment, the trial was terminated after treatment of 25 patients. Treatment with AFM13 was well tolerated: only two treatment-associated serious adverse events (SAEs) were reported; all SAEs resolved completely. With an objective response rate (ORR) of 16.7% (1/5 in arm A, 1/11 in arm B, and 2/8 in arm C) and a 12-month progression-free survival (PFS) of 12.6% (95% CI 3.2–28.9), treatment efficacy of AFM13 monotherapy in all evaluable patients was modest. The continuous application schedule (arm C) might be more effective, but the visit schedule should be better aligned with patients’ daily life.
科研通智能强力驱动
Strongly Powered by AbleSci AI